ValuEngine upgraded shares of Versartis (NASDAQ:VSAR) from a hold rating to a buy rating in a research note released on Monday.
NASDAQ VSAR opened at $1.75 on Monday. The company has a current ratio of 16.99, a quick ratio of 16.99 and a debt-to-equity ratio of 0.11. The company has a market cap of $62.51 million, a P/E ratio of -0.73 and a beta of 1.89. Versartis has a 1 year low of $1.35 and a 1 year high of $22.10.
Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.96) by $0.69. equities analysts expect that Versartis will post -3.15 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of VSAR. Millennium Management LLC lifted its stake in Versartis by 50.4% in the 2nd quarter. Millennium Management LLC now owns 809,698 shares of the biopharmaceutical company’s stock valued at $1,640,000 after purchasing an additional 271,458 shares during the last quarter. Nexthera Capital LP bought a new position in Versartis in the 2nd quarter valued at approximately $1,013,000. Sio Capital Management LLC bought a new position in Versartis in the 2nd quarter valued at approximately $504,000. Paloma Partners Management Co bought a new position in Versartis in the 2nd quarter valued at approximately $325,000. Finally, Baker BROS. Advisors LP lifted its stake in Versartis by 70.1% in the 2nd quarter. Baker BROS. Advisors LP now owns 2,426,310 shares of the biopharmaceutical company’s stock valued at $4,913,000 after purchasing an additional 1,000,000 shares during the last quarter. Institutional investors and hedge funds own 37.15% of the company’s stock.
See Also: Short Selling Stocks, A Beginner’s Guide
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.